NCI-H1993 Cells

The NCI-H1993 cell line is a human non-small cell lung cancer (NSCLC) model derived from a metastatic site in a male patient. Classified as an adenocarcinoma, this cell line is notable for its MET gene amplification, which drives tumor growth and enhances invasive characteristics. MET amplification in NCI-H1993 results in constitutive activation of the hepatocyte growth factor (HGF)/MET signaling pathway, promoting cell proliferation, survival, and metastasis. This makes NCI-H1993 a critical model for studying MET-driven oncogenesis and evaluating targeted therapeutic agents.

NCI-H1993 has been extensively utilized in the preclinical assessment of MET inhibitors such as crizotinib and tepotinib. These inhibitors have demonstrated significant efficacy in suppressing MET signaling, reducing tumor cell proliferation and inducing apoptosis. The cell line’s responsiveness to MET inhibition highlights its utility in translational research aimed at developing treatments for MET-driven cancers. In addition to MET-targeted studies, NCI-H1993 has been used to explore the interplay between MET signaling and other oncogenic pathways, such as the PI3K/AKT and RAS/RAF/ERK cascades.

Recent investigations into the response of NCI-H1993 to glucocorticoid receptor (GR) agonists like dexamethasone have revealed novel insights. The cell line exhibits GR-mediated growth arrest at the G1/S phase transition, accompanied by metabolic reprogramming and reduced migration. These findings suggest potential combinatorial therapeutic strategies involving GR agonists and MET inhibitors for treating advanced NSCLC. The robust genetic and molecular characterization of NCI-H1993 continues to support its role as a pivotal tool for advancing the understanding of lung adenocarcinoma biology and therapy development.